Uso apropiado de la terapéutica en pacientes con miocardiopatía hipertrófica obstructiva

Abstract

Hypertrophic cardiomyopathy is the leading cause of death in young patients, and occurs in 1 in 500 people worldwide, which represents a pathology of universal interest. Its diagnosis at the beginning of the disease can be overlooked by the few symptoms, for this reason the family history is substantial, to carry out a control and modify its natural evolution. The treatment is necessary to establish it from the beginning to prevent the disease from progressing and having to resort to other invasive therapeutic alternatives of greater complexity and costly for the patient. Objectives: To analyze pharmacological and surgical treatment in patients with obstructive hypertrophic cardiomyopathy. Methods: obtaining information is through research from scientific sources based on articles, European and American guidelines and clinical trials, from past information to the most up-to-date. Conclusions: the early application of medical treatment and preventive measures are fundamental for the rapid progression of the disease, in the same way in patients with obstruction and mitral regurgitation, the most appropriate therapy is mitral valve repair miectomía